Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
LZTS1 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | Q9Y250 |
| Other Accession | NP_066300.1 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 66613 Da |
| Antigen Region | 77-105 aa |
| Gene ID | 11178 |
|---|---|
| Other Names | Leucine zipper putative tumor suppressor 1, F37/esophageal cancer-related gene-coding leucine-zipper motif, Fez1, LZTS1, FEZ1 |
| Target/Specificity | This LZTS1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 77-105 amino acids from the N-terminal region of human LZTS1. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | LZTS1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | LZTS1 |
|---|---|
| Synonyms | FEZ1 |
| Function | Involved in the regulation of cell growth. May stabilize the active CDC2-cyclin B1 complex and thereby contribute to the regulation of the cell cycle and the prevention of uncontrolled cell proliferation. May act as a tumor suppressor. |
| Cellular Location | Cytoplasm. Cell membrane. Cell projection, dendritic spine Postsynaptic density. Synapse Note=Associated with the plasma membrane and with microtubules Detected in dendritic spines, especially in the postsynaptic density (By similarity). |
| Tissue Location | Highly expressed in testis, prostate, spleen, thymus, ovary and brain. Detected at lower levels in heart, placenta, small intestine, colon, liver, kidney, skeletal muscle and pancreas Not detectable in primary tumors from breast and prostate and in many cancer cell lines. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a tumor suppressor protein that is ubiquitously expressed in normal tissues. In uveal melanomas, expression of this protein is silenced in rapidly metastasizing and metastatic tumor cells but has normal expression in slowly metastasizing or nonmetastasizing tumor cells. This protein may have a role in cell-cycle control by interacting with the Cdk1/cyclinB1 complex. This gene is located on chromosomal region 8p22. Loss of heterozygosity (LOH) in the 8p arm is a common characteristic of many types of cancer.
References
Olson, J.E., et al. Breast Cancer Res. Treat. (2010) In press :
Chattopadhyay, I., et al. Mutat. Res. 696(2):130-138(2010)
Califano, D., et al. J. Cell. Physiol. 222(2):382-386(2010)
Shyn, S.I., et al. Mol. Psychiatry (2009) In press :
Canova, C., et al. Cancer Res. 69(7):2956-2965(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
